Floxacillin

Floxacillin

SCHEMBL22651560

Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2C(C(=O)O)C(C)(C)S[C@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Floxacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 3/20 1.00
CYP1A2 P05177 1/20 1.00
LMNA P02545 3/20 0.84
HPGD P15428 4/20 0.76
MEN1 O00255 2/20 0.76
KMT2A Q03164 2/20 0.76
TDP1 Q9NUW8 1/20 0.76
SLCO1B3 Q9NPD5 1/20 0.75
SLCO1B1 Q9Y6L6 1/20 0.75
ALDH1A1 P00352 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
PTGS1 P23219 1/20 0.56
PDE3A Q14432 1/20 0.56
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Floxacillin SCHEMBL3823 1.00 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL14126462 1.00 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL1458003 1.00 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL1442294 0.99 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL21643600 0.99 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL855083 0.99 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL2636814 0.98 ABCB11 (0.97) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL28086634 0.96 ABCB11 (0.92) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL11407708 0.95 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL11407710 0.95 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346879-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-11-02 US disclosed
US-20230346879-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-11-02 US disclosed
US-11564970-B2 Compositions and methods for combinatorial drug discovery in nanoliter droplets THE BROAD INSTITUTE, INC. (US) 2023-01-31 US disclosed
US-20200353033-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS THE BROAD INSTITUTE, INC. (US) 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346879-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS RAB5IF, CLTB, TBK1 ABCB11 2506/4885CYP1A2 4441/4885LMNA 3886/4885
US-20200353033-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS RAB5IF, CLTB, TBK1 ABCB11 2506/4885CYP1A2 4441/4885LMNA 3886/4885
US-11564970-B2 Compositions and methods for combinatorial drug discovery in nanoliter droplets RAB5IF, LIPA, CLTB ABCB11 2534/4885CYP1A2 4134/4885LMNA 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.